1 / 7

Hemoglobinopathies Market 2019: Future Trends, Key Players To 2026

The study segments the Hemoglobinopathies industry in light of major classification such as product type, potential markets, application, and end-user.

Rugvedapatel
Download Presentation

Hemoglobinopathies Market 2019: Future Trends, Key Players To 2026

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hemoglobinopathies Market To Reach USD 13.68 Billion By 2026

  2. Market Summary Insufficient healthcare infrastructure and low levels of disease diagnosis and treatments, rising prevalence of hemoglobin disorders such as Sickle Cell Disease, thalassemia, Hb C, and Hb E are expected to be high impact growth drivers for the market.Market Size – USD 5.31 Billion in 2018, Market Growth - CAGR of 10.2%, Market Trends – Product launches and research for advanced Hemoglobinopathies MarketAccording to the current analysis of Reports and Data, the global Hemoglobinopathies market was valued at USD 5.31 Billion in 2018 and is expected to reach USD 13.68 Billion by year 2026, at a CAGR of 10.2% from 2019-2026.Hemoglobinopathies is a genetic defect that results in abnormal structure of one of the globin chains of the hemoglobin molecule. Hemoglobinopathy disorders include sickle cell anemia, hemoglobin C disease, hemoglobin S-C disease, and various forms of thalassemia.The growth of the hemoglobinopathies market is driven by the increasing prevalence of hemoglobinopathies in developed countries, high-level diseases, a variety of government support initiatives and NGO funding. Advanced diagnostic and therapeutic factors, favorable diagnostic and economical approaches such as genetic testing and developing rapid point of care diagnostic methods are other factors that drive the global hemoglobinopathy market. The hemoglobinopathies market is distributed mainly into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa (MEA). According to WHO, around 300,000 to 500,000 children born each year are affected by hemoglobin disorders. www.reportsanddata.com

  3. Further key findings from the report suggest • The Global Hemoglobinopathy market is projected to register a CAGR of 10.2% during the forecast period in terms of value. • The global hemoglobinopathies treatment market is concentrated towards the drivers and the market being in a growth phase, the competition among companies is intense. • North America leads the overall hemoglobinopathies market in terms of revenue in 2018 while Asia pacific is expected to show lucrative growth over the forecast period owing to the presence of high unmet clinical needs, and improving healthcare infrastructure. • The main drivers for hemoglobinopathies market are growing prevalence of hemoglobinopathies in developed nations, high disease occurrence in underdeveloped nations, various supportive government initiatives, and non-government organizational funding. • There are some of the drugs NiCord, ZFP Transcription Factors, ALN-TMP, Drug Targeting PRMT5 which are used for hemoglobinopathies treatment, which are expected to cumulatively boost the market growth. • North America leads the overall hemoglobinopathies market in terms of revenue in 2018 with market share of 39% in 2018 and this market is expected to reach USD 52.71 billion in 2026. • The market for red blood cells count test segment is expected to reach USD 25.05 billion by year 2026, growing at a highest CAGR of 10.5% during the forecast period. • Sickle cell disease is the leading product segment of the global Hemoglobinopathies market with highest market share of 52.4%.

  4. Market Summary • Key Players: • Alnylam Pharmaceuticals, Gamida Cell, Biogen Idec, AcceleronPharma, SangamoBioSciences, Anthera Pharmaceuticals, Global Blood Therapeutics, Geetix Pharmaceuticals, Mast Therapeutics, Prolong Pharmaceuticals, Emmaus Medical, Celgene Corporation, Invenux, Optinova Ab, and HemaQuest Pharmaceuticals • Segmentation: • For the purpose of this report, Reports and Data has segmented the Hemoglobinopathies market on the basis of type, Therapy Type, Test type, and region: • Type (Revenue, USD Million; 2016–2026) • Thalassemia • Sickle Cell Disease • Other Hb Variants Diseases • Therapy Type (Revenue, USD Million; 2016–2026) • Blood transfusion • Iron chelation therapy • Bone marrow transplant • Others To look at the PDF Sample Report and get 30 minutes of a free consultation @ https://www.reportsanddata.com/sample-enquiry-form/2165 www.reportsanddata.com

  5. Market Summary • Test Type (Revenue, USD Million; 2016–2026) • Red blood cell (RBC) count test • Genetic testing • Liquid chromatography (HPLC) test • Hemoglobin isoelectric (Hb IEF) focusing • Hemoglobin electrophoresis (Hb ELP) test • Hemoglobin solubility test. • Regional Outlook (Revenue in USD Million; 2016–2026) • North America • Europe • Asia Pacific • Latin America • Middle East & Africa (MEA) • Rest of MEA Grab Your Report at an Impressive Discount! Please Click Here : https://www.reportsanddata.com/make-enquiry-form/2165 www.reportsanddata.com

  6. The report emphasizes the following key questions: Q.1.What are the most lucrative and promising growth prospects for the market? Q.2.Which sectors are expected to deliver a high growth rate and which industry aspects come into play in this advancement? Q.3.Which geographies are estimated to exhibit the highest growth and the underlying causes? Q.4.Which factors are impacting the future of the market and what are the driving factors? Q.5.What are the hurdles and challenges curtailing the industry’s growth in the forecast period? www.reportsanddata.com

  7. About Us Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Contact Us: John Watson Head of Business Development Reports And Data | Web: www.reportsanddata.com Direct Line: +1-212-710-1370 E-mail: sales@reportsanddata.com

More Related